ODDITY Q3 2026: Revenue decline narrows to 2%, profitability returns, full-year guidance raised

What happened

ODDITY Tech reported Q3 2026 net revenue of $145 million, down only 2% year-over-year compared with a 26% decline in Q1 2026, showing the steepest part of the revenue reset is likely behind the company. Adjusted EBITDA recovered to $22 million from a negative $7 million in Q1 2026, and net income swung to a positive $11 million, indicating the ad-efficiency repair is translating into operating leverage. The company raised its full-year net revenue and adjusted EBITDA outlook, management now projecting a faster normalization of customer acquisition costs than previously assumed. The balance sheet remains strong with $561 million in cash and investments and $350 million of undrawn credit facilities, providing ample runway to continue rebuilding the customer cohort base. The results align with the strongest scenario in the prior DeepValue framework, which had required Q3 evidence of further CPA improvement and first-order stabilization; while single-partner ad dependence remains a risk, the immediate operating pressure has clearly eased.

Implication

The dramatic improvement in revenue trajectory and return to profitability suggest the advertising platform disruption was temporary rather than structural, which was the central uncertainty in the prior WAIT rating. With the full-year guidance raised, the market now has a stronger basis to price in a recovery toward the base-case implied value of $18, and possibly higher if first-order volumes continue to rebuild into 2027. However, investors should remain alert to the still-high dependence on a single major ad partner and the lack of channel diversification; any new algorithmic changes could disrupt the funnel again. The next critical checkpoint is whether Q4 2026 maintains sequential improvement and whether the company can sustain adjusted EBITDA margins above 10%, which would support a re-rating toward the bull-case implied value of $26. A disciplined approach would be to accumulate shares below $20 while monitoring monthly CPA trends and first-order commentary in the next earnings release.

Thesis delta

The prior thesis was a WAIT: buy only with proof within six months that CAC normalization was real and first-order volumes were rebuilding. Q3 2026 delivered that proof: revenue decline narrowed to 2%, adjusted EBITDA turned positive at $22 million, and full-year guidance was raised. The thesis now shifts to a cautious BUY with the primary risk being continued reliance on one advertising partner; the attractive entry level moves up from $14 to approximately $18-$20.